PyL in Patients With High Risk and Biochemically Recurrent Prostate Cancer
ConditionProstate Cancer
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexMale
Age18+
SponsorHoag Memorial Hospital Presbyterian
About this trial
The standard of care imaging of prostate cancer metastases recommended by the National Comprehensive Cancer Network (NCCN), CT of the chest/abdomen/pelvis and bone scan, may be suboptimal. PyL is a novel PET tracer designed to detect prostate specific membrane antigen (PSMA) expressed on prostate cancer cells. PyL PET/CT may provide improved evaluation of clinically significant metastases in patients with prostate cancer.
Eligibility criteria
Qualifiers
Male ≥ 18 years of age.
Histologically confirmed adenocarcinoma of the prostate
Disqualifiers
Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data.
Patients who cannot undergo PET/CT scanning because of weight limits. PET/CT scanners may not be able to function with patients over 450 pounds.
Change in therapy since standard of care imaging
Trial design
Treatments tested in this trial
- DCFPyL PET/CT
Treatment groups
184 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov